Generics - UCB

Filter

Current filters:

UCB

Popular Filters

Actavis confirms patent challenge for generic Neupro

Actavis confirms patent challenge for generic Neupro

23-08-2014

Ireland-headquartered generics major Actavis on Friday confirmed that it has filed an Abbreviated New…

ActavisGenericsLegalNeuproNeurologicalPatentsRegulationUCBUSA

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz

04-07-2013

US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

UCB buys majority stake in local drugmaker to expand in Brazil

31-05-2012

Belgium's leading pharma company UCB (Euronext Brussels: UCB) says it has signed an agreement to acquire…

GenericsMeizler BiopharmaMergers & AcquisitionsPharmaceuticalSouth AmericaUCB

Opportunities for Pharma in narcolepsy

20-02-2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Mylan debuts innovative version of levetiracetam

19-01-2012

US generic drugmaker Mylan (Nasdaq: MYL) says that its Mylan Institutional business has launched Levetiracetam…

GenericsKeppraLevetiracetamMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaUCB

Parexel

Parexel

Back to top